Chronic Myeloid Leukemia: From Daily Management to Complicated Issues

Celalettin Ustun (Editor)
Department of Medicine, University of Minnesota, Minneapolis, MN, USA

Uday R. Popat (Editor)
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Clear

$240.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Targeted therapy has revolutionized modern oncology practice and has completely changed the outcome of once universally fatal diseases like chronic myeloid leukemia (CML). The last decade has witnessed significant advances in the management of CML, which has become more like a chronic disease. Written by experts in the field, this volume nicely describes the current knowledge of the pathophysiology, clinical features, and management of CML. It covers not only clinical topics but also the basic science underlying these practices. It will be of help to clinicians and basic scientists alike.

In addition to the state of the art treatment of CML, this book also covers many uncommon but very important special topics like management of CML in pregnancy or with children, management of resistance to new tyrosine kinases and treatment of the advanced phase of the disease. Written to be easily digestible, patients will also be able to access important and universally useful information on CML (e.g., diagnosis, symptoms and signs, and treatment). Some themes especially, including drug and food interactions of tyrosine kinase inhibitors (TKIs), CML treatment during pregnancy, advantages/disadvantages of the most commonly used TKIs, and bone marrow transplantation indications, will be of popular concern. This extensively referenced book therefore should be of great help to both novices and experts in the field. (Imprint: Nova Biomedical )

Preface

Section I

Chapter 1. Definition, Epidemiology, Natural History and Clinical Phases
(Vamsi Kota and Kavita Natarajan, Georgia Regents University, Augusta, GA, USA)

Section II

Chapter 2. CML: Clinical Diagnosis, Differential Diagnosis and Scoring Systems
(Nelli Bejanyan, University of Minnesota, Minneapolis, MN, USA)

Chapter 3. Chronic Myelogenous Leukemia, Morphology and Immunophenotype
(Melissa Hart and Michael Linden, Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA)

Chapter 4. Cytogenetic and Molecular Aspects of CML
(Michelle Dolan, Michael Spears, and Sophia Yohe, Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA)

Chapter 5. Molecular Mechanisms in CML Pathogenesis
(Vamsi Kota and Jerald P. Radich, Georgia Regents University, Augusta, GA, USA and others)

Chapter 6. Secondary Resistance to Tyrosine Kinase Inhibitors: Focus on Molecular Mechanisms other than BCR-ABL Overexpression and Mutations
(Tereza Lopotová and Markéta Žáèková, Institute of Hematology and Blood Transfusion, Dept. of Cellular Biochemistry, U Nemocnice 1, Prague, Czech Republic)

Section III

Chapter 7. Frontline Therapy
(Pavan Kumar Bhamidipati and Elias Jabbour, Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX, USA)

Chapter 8. Management of Tyrosine Kinase Inhibitors Resistance
(Pavan Kumar Bhamidipati and Elias Jabbour, Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX, USA)

Chapter 9. Management of Chronic Myeloid Leukemia (CML): Accelerated Phase (AP)
(Mohamad Cherry and Aref Al-Kali, Oklahoma University Health Science Center, Oklahoma City, OK, USA and others)

Chapter 10. Management of Chronic Myeloid Leukemia (CML): Blast Phase (BP)
(Aref Al-Kali, Pavan Kumar Bhamidipati and Elias Jabbour, Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA and others)

Chapter 11. Hematopoietic Cell Transplant for CML
(Fiona He and Erica Warlick, Department of Medicine, and Division of Hematology, Oncology, and Transplant, Department of Medicine,
University of Minnesota, USA)

Chapter 12. Summary of Treatment and Recommended Follow-Up of CML Patients
(Celalettin Ustun, Erica Warlick, Prithviraj Bose, Jerald P. Radich and John Goldman, Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, USA and others)

Section IV

Chapter 13. CML in Pediatric Population
(Michael Burke and Lamis Eldjerou, Medical College of Wisconsin, MACC Fund Research Center, Division of Pediatric Hematology-Oncology-BMT, Milwaukee, WI, USA and others)

Chapter 14. Blastic Transformation in Extramedullary Sites
(Isabel Cunningham, Division of Hematology Oncology, Columbia University College of Physicians and Surgeons, New York, NY, USA)

Chapter 15. Managing CML in Pregnancy
(Renuka Palanicawandar, Jane Apperley and Deepti Radia, Centre for Haematology, Imperial College London, London, UK and others)

Chapter 16. Drug and Food Interactions with TKIs
(David DeRemer, University of Georgia College of Pharmacy, Georgia Regents University Cancer Center, GA, USA)

Chapter 17. Molecular Monitoring of CML: Role for Novel Markers Additional to BCR-ABL
(Tereza Lopotová and Markéta Žáèková, Institute of Hematology and Blood Transfusion, Department of Cellular Biochemistry, Prague, Czech Republic)

Section V

Chapter 18. Can We Cure CML without Transplantation?
(Prithviraj Bose and Pankit Vachhani, Massey Cancer Center and the Department of Internal Medicine, Virginia Commonwealth University, VA, USA)
Free Download Available

Commentary

Chapter 19. Future Directions
(Celalettin Ustun and John Goldman, Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, MN, USA and others)

Index

Audience: We are humbled to introduce the excellent contributions to, Chronic Myeloid Leukemia: From Daily Management to Complicated Issues, written by esteemed experts in chronic myeloid leukemia (CML). As practicing hematologists and academicians, we believe that this book will serve a diverse audience of medical students, community oncologists, and academic hematologists and their patients.

You have not viewed any product yet.